Researchers determined IL-26 serves as a potent antimicrobial that promotes the immune sensing of both bacterial and host cell death…

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Researchers determined IL-26 serves as a potent antimicrobial that promotes the immune sensing of both bacterial and host cell death…
David Douglas |
NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) are at slightly increased risk of invasive pneumococcal disease (IPD), according to Danish researchers. In a paper online Sept. 8 in The American Journal of Gastroenterology, Bjørn Kantsø of Statens Serum Institut in Copenhagen and colleagues note that the inappropriate immune response against infective agents seen in…
American College of Rheumatology |
ATLANTA—The American College of Rheumatology (ACR) has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA). The guideline was developed with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network. It summarizes recommendations for both pharmacologic and non-pharmacologic treatments, including rehabilitation, management of patients with…
David Douglas |
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…

A recent study analyzed inflammasome response, finding the POP1 PYRIN domain protein acts to decrease excessive inflammatory responses and prevent systemic inflammation. Researchers ultimately developed a drug based on POP1 and found it reduced inflammation in mice…
Rob Goodier |
NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found. “The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London…

Researchers recommend rheumatologists factor in a patient’s ability to pay when determining treatment, because their study found that an arthritis diagnosis may substantially affect patient finances…

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Paul Hoover, MD, PhD, & Lindsey MacFarlane, MD |
A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…

“Love is the bone and sinew of my curse.” —Sylvia Plath Cutting the Cord Here’s the problem: No one grows up wanting to seek the cure for bursitis—or tendonitis or just about any of the other seemingly mundane maladies afflicting our body’s scaffolding. Meniscal tears, fasciitis, tendinopathies—the list is endless. Chances are, your college essay…